Azetidine, pyrrolidine and piperidine derivatives as 5HT1 recept

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

514331, 514376, 514415, 514414, 546208, 548221, 548468, 548491, A61K 31445, C07D20902, C07D40100, C07D26358

Patent

active

060253746

DESCRIPTION:

BRIEF SUMMARY
The present invention relates to a class of substituted azetidine, pyrrolidine and piperidine derivatives which act on 5-hydroxytryptamine (5-HT) receptors, being selective agonists of so-called "5-HT.sub.1 -like" receptors. They are therefore useful in the treatment of clinical conditions for which a selective agonist of these receptors is indicated.
It has been known for some time that 5-HT.sub.1 -like receptor agonists which exhibit selective vasoconstrictor activity are of use in the treatment of migraine (see, for example, A. Doenicke et al., The Lancet, 1988, Vol. 1, 1309-11; and W. Feniuk and P. P. A. Humphrey, Drug Development Research, 1992, 26, 235-240).
The human 5-HT.sub.1 -like or 5-HT.sub.1D receptor has recently been shown by molecular cloning techniques to exist in two distinct subtypes. These subtypes have been termed 5-HT.sub.1D.alpha. (or 5-HT.sub.1D-1) and 5-HT.sub.1D.beta. (or 5-HT.sub.1D-2), and their amino acid sequences are disclosed and claimed in WO-A-91/17174.
The 5-HT.sub.1D.alpha. receptor subtype in humans is believed to reside on sensory terminals in the dura mater. Stimulation of the 5-HT.sub.1D.alpha. subtype inhibits the release of inflammatory neuropeptides which are thought to contribute to the headache pain of migraine. The human 5-HT.sub.1D.beta. receptor subtype, meanwhile, is located predominantly on the blood vessels and in the brain, and hence may play a part in mediating constriction of cerebral and coronary arteries, as well as CNS effects.
Administration of the prototypical 5-HT.sub.1D agonist sumatriptan (GR43175) to humans is known to give rise at therapeutic doses to certain adverse cardiovascular events (see, for example, F. Willett et al., Br. Med. J., 1992, 304, 1415; J. P. Ottervanger et al., The Lancet, 1993, 341, 861-2; and D. N. Bateman, The Lancet, 1993, 341, 221-4). Since sumatriptan barely discriminates between the human 5-HT.sub.1D.alpha. and 5-HT.sub.1D.beta. receptor subtypes (cf. WO-A-91/17174, Table 1), and since it is the blood vessels with which the 5-HT.sub.1D.beta. subtype is most closely associated, it is believed that the cardiovascular side-effects observed with sumatriptan can be attributed to stimulation of the 5-HT.sub.1D.beta. receptor subtype. It is accordingly considered (cf. G. W. Rebeck et al., Proc. Natl. Acad. Sci. USA, 1994, 91, 3666-9) that compounds which can interact selectively with the 5-HT.sub.1D.alpha. receptor subtype, whilst having a less pronounced action at the 5-HT.sub.1D.beta. subtype, might be free from, or at any rate less prone to, the undesirable cardiovascular and other side-effects associated with non-subtype-selective 5-HT.sub.1D receptor agonists, whilst at the same time maintaining a beneficial level of anti-migraine activity.
The compounds of the present invention, being selective 5-HT.sub.1 -like receptor agonists, are accordingly of benefit in the treatment of migraine and associated conditions, e.g. cluster headache, chronic paroxysmal hemicrania, headache associated with vascular disorders, tension headache and paediatric migraine. In particular, the compounds according to this invention are potent agonists of the human 5-HT.sub.1D.alpha. receptor subtype. Moreover, the compounds in accordance with this invention have been found to possess at least a 10-fold selective affinity for the 5-HT.sub.1D.alpha. receptor subtype relative to the 5-HT.sub.1D.beta. subtype, and they can therefore be expected to manifest fewer side-effects than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists.
Several distinct classes of heteroaromatic compounds based on inter alia a substituted tryptamine ring system are described in published International patent applications 91/18897, 94/02460 and 94/02477. The compounds described therein are stated to be agonists of 5-HT.sub.1 -like receptors, and accordingly to be of particular use in the treatment of migraine and associated conditions. None of these publications, however, discloses or even suggests the substituted azetidine, pyrrolidine and piperidi

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Azetidine, pyrrolidine and piperidine derivatives as 5HT1 recept does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Azetidine, pyrrolidine and piperidine derivatives as 5HT1 recept, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azetidine, pyrrolidine and piperidine derivatives as 5HT1 recept will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-1906216

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.